source: The Journal of Clinical Endocrinology and Metabolism
Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J
Radioiodine is an effective and safe treatment for hyperthyroidism but has been implicated as a risk factor for deterioration or new presentation of Graves’ ophthalmopathy (GO). Prophylactic glucocorticoids appear to prevent this effect.
The objective of this study was to document the course of GO after radioiodine therapy.
This was a prospective observational study. Patients were assessed at baseline and 2, 4, 6, and 12 months after radioiodine therapy.
The study was conducted at a tertiary referral center.
Seventy-two GO patients with minimally active eye disease participated in the study.
A fixed dose of radioiodine was administered. T(4) was commenced 2 wk later to prevent hypothyroidism.
Main Outcome Measures:
Change in activity and severity of GO were analyzed.
Exophthalmometer readings, the width of the palpebral aperture, diplopia scores, and the clinical activity score improved significantly. By clinically significant criteria, the eye disease improved in four patients (transiently in three of the four cases), most likely attributable to the natural course of the disease. No patient’s eyes deteriorated.
Radioiodine is not associated with deterioration of GO in patients with minimally active eye disease when postradioiodine hypothyroidism is prevented.
Freeman Hospital, UK
full text source